Combined XIL‐6R and urocortin‐2 treatment restores MDX diaphragm muscle force
- 29 May 2017
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 56 (6) , E134-E140
Abstract
Introduction: Duchenne muscular dystrophy (DMD) is characterized by progressive muscle degeneration leading to immobility, respiratory failure, and premature death. As chronic inflammation and stress are implicated in DMD pathology, the efficacy of an anti‐inflammatory and anti‐stress intervention strategy in ameliorating diaphragm dysfunction was investigated. Methods: Diaphragm muscle contractile function was compared in wild‐type and dystrophin‐deficient mdx mice treated with saline, anti‐interleukin‐6 receptor antibodies (xIL‐6R), the corticotrophin‐releasing factor receptor 2 (CRFR2) agonist, urocortin 2, or both xIL‐6R and urocortin 2. Results: Combined treatment with xIL‐6R and urocortin 2 rescued impaired force in mdx diaphragms. Mechanical work production and muscle shortening was also improved by combined drug treatment. Discussion: Treatment which neutralizes peripheral IL‐6 signaling and stimulates CRFR2 recovers force‐generating capacity and the ability to perform mechanical work in mdx diaphragm muscle. These findings may be important in the search for therapeutic targets in DMD. Muscle Nerve 56: E134–E140, 2017Keywords
Funding Information
- Muscular Dystrophy Ireland
- Department of Physiology, UCC
- Chugai Pharmaceuticals, Tokyo, Japan
This publication has 62 references indexed in Scilit:
- Diaphragm weakness in mechanically ventilated critically ill patientsCritical Care, 2013
- IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouseBMC Musculoskeletal Disorders, 2012
- Alterations in the expression of leukemia inhibitory factor following exercise: comparisons between wild-type and mdx musclesPLoS Currents, 2011
- Mechanisms inducing low bone density in duchenne muscular dystrophy in mice and humansJournal of Bone and Mineral Research, 2011
- The Dystrophin‐Glycoprotein Complex in the Prevention of Muscle DamageBioMed Research International, 2011
- Malformed mdx myofibers have normal cytoskeletal architecture yet altered EC coupling and stress-induced Ca2+ signalingAmerican Journal of Physiology-Cell Physiology, 2009
- Major basic protein-1 promotes fibrosis of dystrophic muscle and attenuates the cellular immune response in muscular dystrophyHuman Molecular Genetics, 2008
- Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx miceBMC Medicine, 2007
- Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2αGut, 2007
- Pathophysiology of Duchenne Muscular Dystrophy: Current HypothesesPediatric Neurology, 2007